Compare Ginkgo Bioworks Holdings Inc (DNA) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs TeraWulf Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while TeraWulf Inc trades at $13.87 (market cap $6.81B). The key difference: TeraWulf Inc is far larger — about 8.9× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and TeraWulf Inc for 17 Days on average.
| DNA | WULF | |
|---|---|---|
Market Cap | $763.64M | $6.81B |
Volume | 3,204,177 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $15.83 | $28.98 |
52-Week Low | $5.48 | $10.99 |
Typical Hold Time | 7 Days | 17 Days |
Enterprise Value | $865.59M | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
WULF trades at $14.40, down 3.81% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The company reported a net loss of -$661.42M in 2025, with revenue of $168.46M, and has missed earnings expectations in recent quarters. Analyst consensus remains strongly bullish with a $34.92 price target, supported by positive news on AI data center leasing trends.
The outlook for WULF hinges on its pivot to AI data center hosting, offering growth potential, but significant risks persist from deep losses, negative margins, and high debt. Investors should weigh analyst optimism against fundamental weaknesses and volatile cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
